[HTML][HTML] Prolonged control of replication-competent dual-tropic human immunodeficiency virus-1 following cessation of highly active antiretroviral therapy

M Salgado, SA Rabi, KA O'Connell, RW Buckheit III… - Retrovirology, 2011 - Springer
M Salgado, SA Rabi, KA O'Connell, RW Buckheit III, JR Bailey, AA Chaudhry, AR Breaud…
Retrovirology, 2011Springer
Background While initiation of highly active antiretroviral therapy (HAART) during primary
HIV-1 infection occasionally results in transient control of viral replication after treatment
interruption, the vast majority of patients eventually experience a rebound in plasma viremia.
Results Here we report a case of a patient who was started on HAART during symptomatic
primary infection and who has subsequently maintained viral loads of< 50 copies/mL for
more than nine years after the cessation of treatment. This patient had a high baseline viral …
Background
While initiation of highly active antiretroviral therapy (HAART) during primary HIV-1 infection occasionally results in transient control of viral replication after treatment interruption, the vast majority of patients eventually experience a rebound in plasma viremia.
Results
Here we report a case of a patient who was started on HAART during symptomatic primary infection and who has subsequently maintained viral loads of < 50 copies/mL for more than nine years after the cessation of treatment. This patient had a high baseline viral load and has maintained a relatively high frequency of latently infected CD4+ T cells. In addition, he does not have any known protective HLA alleles. Thus it is unlikely that he was destined to become a natural elite controller or suppressor. The mechanism of control of viral replication is unclear; he is infected with a CCR5/CXCR4 dual-tropic virus that is fully replication-competent in vitro. In addition, his spouse, who transmitted the virus to him, developed AIDS. The patient's CD4+ T cells are fully susceptible to HIV-1 infection, and he has low titers of neutralizing antibodies to heterologous and autologous HIV-1 isolates. Furthermore, his CD8+ T cells do not have potent HIV suppressive activity.
Conclusion
This report suggests that some patients may be capable of controlling pathogenic HIV-1 isolates for extended periods of time after the cessation of HAART through a mechanism that is distinct from the potent cytotoxic T lymphocyte (CTL) mediated suppression that has been reported in many elite suppressors.
Springer